Lincoln Pharmaceuticals Q2 Results FY27: Revenue Up 17.13% to Rs 191.35 Cr, PAT Rs 20.43 Cr

Lincoln Pharmaceuticals Ltd (LINCOLN) Q2 Results FY27 announced on 29 October 2026, covering the company's financial performance for the July to September quarter. The results date brings consolidated results with revenue of Rs 191.35 Cr against Rs 163.36 Cr a year earlier and net profit (PAT) of Rs 20.43 Cr against Rs 19.98 Cr. Lincoln Pharmaceuticals Q2 Results FY27 also show Operating Profit of Rs 23.69 Cr, down from Rs 25.43 Cr.

This results analysis of Lincoln Pharmaceuticals Q2 Results covers the financial highlights, business drivers, outlook and risks, with Univest data used throughout. The Financial Highlights table below sets out every metric against the same quarter last year.

Click Here – Get Free Investment Predictions

Lincoln Pharmaceuticals Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 191.35 Cr	Rs 163.36 Cr	+17.13% YoY
Operating Profit	Rs 23.69 Cr	Rs 25.43 Cr	-6.84% YoY
Net Profit (PAT)	Rs 20.43 Cr	Rs 19.98 Cr	+2.25% YoY

Source: company filing for Lincoln Pharmaceuticals Q2 Results FY27, 29 October 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from Lincoln Pharmaceuticals Q2 Results: What Stands Out

• Revenue of Rs 191.35 Cr grew 17.13% YoY from Rs 163.36 Cr in the comparison quarter, which is clear YoY growth on the top line.
• Net profit of Rs 20.43 Cr rose 2.25% YoY from Rs 19.98 Cr, a much smaller gain than the increase in revenue.
• Operating Profit of Rs 23.69 Cr fell 6.84% YoY from Rs 25.43 Cr, so profit at this level moved against revenue.
• Net profit margin of 10.7% compares with 12.2% a year ago, a point that sits among the risks in Lincoln Pharmaceuticals Q2 Results FY27.
• Revenue was down 3.0% QoQ from Rs 197.28 Cr, and the performance analysis below explains how these figures fit together.

Lincoln Pharmaceuticals Q2 Results FY27: Performance Analysis

Lincoln Pharmaceuticals Q2 Results FY27 show revenue growing faster than profit. Revenue rose 17.13% YoY to Rs 191.35 Cr, net profit rose 2.25% YoY to Rs 20.43 Cr, and Operating Profit fell 6.84% YoY to Rs 23.69 Cr. This results analysis therefore shows top-line YoY growth with a narrower gain at the bottom line.

Compared with the same quarter last year, revenue moved up by Rs 27.99 Cr, while net profit moved up by Rs 0.45 Cr. In the Lincoln Pharmaceuticals Q2 Results, the gap between these two changes is the main point investors will track across coming quarterly results.

Operating Profit declined by Rs 1.74 Cr YoY even as revenue grew, and net profit stayed close to last year's level. Univest users can follow how these three lines develop in later filings, since Lincoln Pharmaceuticals Q2 Results FY27 form the base for that comparison. The business factors behind these numbers come next.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis starts with revenue, which grew 17.1% year on year to Rs 191.35 Cr in the latest quarter. This is the clearest driver in Lincoln Pharmaceuticals Q2 Results FY27, although the data confirms the growth without establishing its specific cause.

Return on Capital Employed – Return on capital employed was 16.27% in FY26. This gives a full-year reference point for the company's use of capital, set beside the figures in these quarterly results for the July to September period.

Low Debt Position – The company is almost debt free, with a debt-to-assets ratio of 0.01 in FY26. This balance sheet position is the background against which the Rs 20.43 Cr net profit and the Rs 191.35 Cr revenue should be read.

FY27 Outlook After Lincoln Pharmaceuticals Q2 Results

FY27 full-year results will depend on the quarters still to come and on disclosed sector conditions. The quarter just reported is the second of the financial year, so the results analysis of later filings will show whether net profit keeps pace with revenue growth.

Within Lincoln Pharmaceuticals Q2 Results FY27, net profit of Rs 20.43 Cr and revenue of Rs 191.35 Cr are the reference points for later quarters. Investors can use the Univest app and the Univest Screener to follow the company's filings. These watch points lead to the risks listed next.

Key Risks to Watch After Lincoln Pharmaceuticals Q2 Results FY27

Narrower Net Profit Margin

Net profit margin narrowed to 10.7% from 12.2% in the comparison quarter. Revenue showed YoY growth of 17.13% while net profit grew only 2.25%, which is how the margin moved lower in Lincoln Pharmaceuticals Q2 Results FY27.

Volatile Quarterly Net Profit

Quarterly net profit has been volatile, ranging from Rs 11.64 Cr to Rs 36.23 Cr over the last 5 quarters. The Rs 20.43 Cr reported now sits inside that range, so the range itself is a risk to track.

Sequential Revenue Dip

Revenue was down 3.0% quarter on quarter from Rs 197.28 Cr. This sequential dip sits alongside the 17.13% revenue gain over last year, so both comparisons matter when reading the quarter.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Lincoln Pharmaceuticals Q2 Results FY27 combine 17.13% revenue growth with a 2.25% rise in net profit and a 6.84% fall in Operating Profit. These consolidated results also carry a narrower margin and a 3.0% sequential revenue dip, so quarterly results from coming quarters will add context. Readers should treat Lincoln Pharmaceuticals Q2 Results as one data point and consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Lincoln Pharmaceuticals Q2 Results FY27

What are Lincoln Pharmaceuticals Q2 Results FY27?

Ans. Lincoln Pharmaceuticals Q2 Results FY27 cover the July to September 2026 quarter, declared on 29 October 2026. Alongside this, revenue was Rs 191.35 Cr and net profit was Rs 20.43 Cr, as set out in the Quick Answer.

What is the results date for Lincoln Pharmaceuticals Q2 Results FY27?

Ans. The results date for Lincoln Pharmaceuticals Q2 Results FY27 is 29 October 2026, when the company declared its July to September quarter numbers. This date is also stated in the opening paragraphs of the article.

What revenue was reported in Lincoln Pharmaceuticals Q2 Results FY27?

Ans. Lincoln Pharmaceuticals Q2 Results FY27 reported revenue of Rs 191.35 Cr, compared with Rs 163.36 Cr a year earlier. This means revenue moved up by Rs 27.99 Cr, as the Financial Highlights table shows.

What net profit was reported in Lincoln Pharmaceuticals Q2 Results FY27?

Ans. Net profit in Lincoln Pharmaceuticals Q2 Results FY27 was Rs 20.43 Cr against Rs 19.98 Cr a year earlier, so the gain was Rs 0.45 Cr. The Performance Analysis section covers this comparison.

How much YoY growth did revenue show in Lincoln Pharmaceuticals Q2 Results FY27?

Ans. Revenue showed YoY growth of 17.13% in Lincoln Pharmaceuticals Q2 Results FY27, while net profit grew 2.25% YoY. Compared with revenue, the profit gain was far smaller, as discussed in the Key Takeaways section.

Did net profit rise or fall in Lincoln Pharmaceuticals Q2 Results?

Ans. Net profit rose 2.25% YoY to Rs 20.43 Cr in Lincoln Pharmaceuticals Q2 Results, which is a small increase. Alongside this, Operating Profit fell, as the Performance Analysis section explains.

What was the Operating Profit in Lincoln Pharmaceuticals Q2 Results FY27?

Ans. Operating Profit in Lincoln Pharmaceuticals Q2 Results FY27 was Rs 23.69 Cr, down 6.84% YoY from Rs 25.43 Cr. This means profit at this level declined by Rs 1.74 Cr, as the Performance Analysis shows.

Are Lincoln Pharmaceuticals Q2 Results consolidated results or standalone results?

Ans. The figures in Lincoln Pharmaceuticals Q2 Results are consolidated results, covering the company on a consolidated basis. This basis applies to every revenue and profit figure in the Financial Highlights table.

What business factors shaped Lincoln Pharmaceuticals Q2 Results FY27?

Ans. The disclosed factors for Lincoln Pharmaceuticals Q2 Results FY27 are 17.1% revenue growth, return on capital employed of 16.27% in FY26 and a debt-to-assets ratio of 0.01 in FY26, as the Key Business Factors section lists.

What are the key risks after Lincoln Pharmaceuticals Q2 Results FY27?

Ans. The risks after Lincoln Pharmaceuticals Q2 Results FY27 are a narrower net profit margin of 10.7%, volatile quarterly net profit and a 3.0% sequential revenue dip. The Key Risks section describes each of these in turn.

What is the outlook after Lincoln Pharmaceuticals Q2 Results?

Ans. Full-year FY27 results after Lincoln Pharmaceuticals Q2 Results will depend on the quarters still to come. Alongside this, net profit of Rs 20.43 Cr and revenue of Rs 191.35 Cr are the reference points described in the Outlook section.

Where can I find the complete Lincoln Pharmaceuticals Q2 Results FY27 data?

Ans. The Financial Highlights table in this article sets out revenue, Operating Profit and net profit against the same quarter last year, while Univest carries further company information on its stock page for Lincoln Pharmaceuticals.